tirzepatide is mounjaro vs Mounjaro: What's the Difference? Mounjaro (Tirzepatide): Raising the Bar

Across GLP-1based therapies, gastrointestinal adverse effects remain the most commonly reported limitation

Our medical director, Dr

Scientific Research Review SURPASS Clinical Trial Program (Type 2 Diabetes) The SURPASS program comprised phase III trials evaluating tirzepatide 5, 10, and 15 mg once weekly in patients with type 2 diabetes: SURPASS-1 (monotherapy, n=478): Tirzepatide reduced HbA1c by 1.87% (5 mg), 1.89% (10 mg), and 2.07% (15 mg) vs

We anticipate seeing human data in the next year, in 2026, Rajagopalan said

(8.1) Females of Reproductive Potential: Advise females using oral contraceptives to switch to a non-oral contraceptive method or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation